Biotechnology for tomorrow's world: Scenarios to guide

2 directions for future innovation

3

4 List of authors:

- 5 Aleksandra Małyska, European Commission, corresponding author,
- 6 <u>aleksandra.malyska@wp.pl;</u> +32472630841
- 7 Marc Cornelissen, BASF, Belgium
- 8 Amrit Kaur Nanda, 'Plants for the Future' European Technology Platform, Belgium
- 9 René Klein Lankhorst, Wageningen University & Research, Netherlands
- 10 Martin A.J. Parry, Lancaster University, UK
- 11 Vandasue Rodrigues Saltenis, Copenhagen Plant Science Centre (CPSC),
- 12 Department of Plant and Environmental Sciences, University of Copenhagen,
- 13 Denmark
- 14 Mathias Pribil, Copenhagen Plant Science Centre (CPSC), Department of Plant and
- 15 Environmental Sciences, University of Copenhagen, Denmark.
- 16 Philippe Nacry, INRA, France
- 17 Dirk Inzé, Ghent University, Belgium
- 18 Alexandra Baekelandt, Ghent University, Belgium
- 19
- 20 Links to Websites:
- 21 CropBooster-P https://www.cropbooster-p.eu/consortium.html
- 22 Wageningen University & Research (Project Coordinator) https://www.wur.nl
- 23 VIB <u>http://www.vib.be/en/Pages/default.aspx</u>
- 24 University of Copenhagen https://www.ku.dk/english/
- 25 INRA http://institut.inra.fr/en
- 26 ETP Plants for the Future <u>http://plantetp.org/</u>
- 27 BASF https://www.basf.com/be/en.html
- 28 Lancaster University https://www.lancaster.ac.uk/
- 29
- 30 Twitter accounts: @Plant_ETP; @Alexandra_Bkldt
- 31 ORCID-ID: 0000-0003-0816-7115
- 32

±

Key words: learning scenarios, biotechnology, Research & Innovation, bioeconomy,
 microbiome, open innovation

35

36 Abstract

37 Depending on how the future will unfold, today's progress in biotechnology research has greater or lesser potential to be the basis of subsequent innovation. Tracking 38 progress against indicators for different future scenarios would enable to focus, 39 emphasize or de-emphasize discovery research timely and to maximize the chance 40 41 for successful innovation. The COVID-19 crisis exemplifies that scenario indicators can offer time advantage to decisions on biotechnology research and innovation 42 43 (R&I) investments, as well as to strategy development to minimize the spread of this type of disease. Tracking indicators that are specific for contrasting learning 44 45 scenarios allows getting insights early in time when uncertainties pan out in a particular way, and can help the biotechnology field with its lengthy innovation 46 47 timelines, high costs and uncertain future markets to develop most effectively. In this paper, we show how learning scenarios with a 2050 time horizon enable to recognize 48 the implications of political and societal developments on the innovation potential of 49 ongoing biotechnological research. We furthermore propose a model to further 50 increase open innovation between academia and the biotechnology value chain to 51 help fundamental research explore discovery fields that have a greater chance to be 52 of value for applied research. 53

54 Developing scenarios for biotechnology in complex social systems

Biological science is expanding its knowledge frontiers at an ever-accelerating pace.
The progressing insights into biological processes offer a broadening array of options
to develop incremental and differential innovations across the medical, agricultural
and industrial biotechnology sectors.

As timelines from understanding basic biological processes to the conception of an innovation and the development of a marketable product may range from ten to twenty-five years, a prime question for today's biotechnology discovery research is "innovation for what future world?" (Fig. 1).

63

To this end, we conducted in 2019 a first of its kind scenario analysis with a 2050

time horizon to understand the option space of agricultural biotechnology

66 (https://www.cropbooster-p.eu/). Forty-five trends and twenty-two uncertainties

67 dealing with the entire agricultural socio-economic system were reviewed to map the

range of directions the future may take and to narrow down how agricultural

69 biotechnology could best future-proof food, nutrition and health security. Trends

ranged from consumer and demographics, farming and technology to politics,

r1 economy and societal developments while identified uncertainties were clustered

around three themes: (1) needs for adaptation, (2) priorities in the value chain, and

73 (3) the role of science (Fig. 2).

74 In order to identify towards which scenario today's world is heading, relevant indicators need to be developed [1,2]. For this, the critical developments or events 75 76 that will be necessary for a scenario to arise need to be named, put in a chronological order through narratives, and checked for their informative value. 77 78 Learning scenarios are reusable, and the scope of the indicators identified will depend on the diversity of expertise within the team exploiting the learning scenarios 79 (Fig 3). Obvious examples of indicators are the developments around the legislation 80 related to gene editing in the Bio-innovation and REJECTech scenario, personal data 81 protection regulations in My choice scenario, while for instance the evolution of water 82 availability in a particular country can be an indicator for Food emergency, as well as 83 for Bio-innovation or REJECTech. 84

85

86 Steering focus in biotechnology discovery research with scenarios

The way the world will evolve will depend on a myriad of developments. Examples 87 are the transition to renewable energy and decentralized storage, the global policy 88 approach to enable the use of new genomic technologies, patients embracing new 89 90 treatments, society buying into preventive medicine or demanding transparency about food properties, dietary shifts, development of new high-tech materials, shifts 91 92 in lifestyle, and progress in robotics and artificial intelligence. Following such 93 developments and extrapolating their long-term impact on the way we live, may 94 inspire scientists to take a translational step and to open avenues of biotechnology

95 discovery research that would provide the starting basis for R&I addressing future96 needs.

Biotechnology discovery research will undoubtedly be at the core of numerous
innovations that will reach society by 2050. However, depending on how the future
will unfold, today's progress in biotechnology research has a greater or lesser
potential to be the basis of subsequent innovation. In addition, the lack of a
widespread open innovation culture between industry and academia increases the
risk of missing out on innovation that trend-wise is likely to meet industry or
consumer demand.

104 For example, it is clear that the demand for climate change related biotechnology innovation will be high, and will be supported by policy makers [3, 4]. However, what 105 106 the unmet needs will be for the different stakeholder groups is still unclear. Effects on 107 cities, gardens, parks, lakes and crop fields linked to shifts and volatility in weather and the resulting new environmental conditions, including new pests and diseases, 108 are not yet fully appreciated. Consequently, a translational step from innovation 109 opportunity to required new knowledge is not obvious. Similarly, it is not clear how to 110 incorporate innovation into products [5]. It may range from gene editing to novel 111 knowledge-driven, societally accepted workflows that are not yet in place. The first 112 113 activity, developing climate change knowhow, has a low risk of not being of relevance. The second, developing biotechnology innovation addressing climate 114 change, is dependent on how policies develop across the globe, and therefore 115 116 carries a higher risk [6]. For example, whereas it is conceivable in a "Bio-innovation" world that society may see a broad replacement of fossil-based synthetic materials 117 118 by bio-based alternatives, such a development is less likely to occur in a "REJECTech" setting, as although the knowhow to do so would exist, the technical 119 120 enablement would not be supported.

Another example relates to the exploitation of the microbiome. As microbes impact
most, if not all, complex ecological systems, exploitation of biological knowhow is
expected to offer innovation options in a broad range of biotechnology fields and be
at the core of new markets and business models. These may include medicine,
healthcare, food systems, industrial and household processes and materials,
resource recycling and energy capture. For this to become reality, broad fundamental

biotechnology discovery research on microbiomes needs to reach a tipping point, so 127 128 that R&I for smaller and bigger opportunities across sectors becomes viable [7]. This 129 necessitates a major public effort to advance pre-competitive knowhow and an 130 enablement to a level sufficient for sector adoption within a reasonable risk 131 perspective on a return of investment. A flagship approach in e.g. medicine building 132 on ongoing big data efforts, such as in the human '100K genomes project' [8], may serve as a vehicle to reach, in a five-year time span, the desired state of enablement 133 and allow smaller initiatives to build on this cost-effectively. However, an 134 135 entrepreneurial ecosystem is critical for this to happen, implying that such 136 developments are more likely to occur under a "Bio-innovation" scenario or even in 137 a "Food emergency" scenario, once society starts prioritizing access to food and 138 health.

139 A third example refers to diet shifts toward alternative protein sources. Consumer choice is highly dependent on food properties such as taste, texture, palatability, 140 141 color, convenience and price. Making alternative protein products competitive to meat would require, amongst other improvements, major advances in biological 142 insights to upgrade food sources [9]. The challenge is to get specific on the carriers, 143 e.g. algae, insects, crops, fermentation, etc., and the exact properties, so that the 144 investments in biotechnology discovery have an effect. To do this successfully is not 145 obvious as it is currently not clear which products and product properties will match 146 147 future market demands. This brings us back to the importance of contrasting learning scenarios and the need to identify scenario-specific indicators to get insights early in 148 time about how particular trends are panning out. These indicators may relate to e.g. 149 150 yes/no decision points in policy development, or the timely establishment of critical enabling technologies or of sizeable consumer demands. Tracking progress of 151 152 multiple (scenario-specific) indicators thus helps to steer focus in discovery research 153 and o emphasize or de-emphasize timely to maximize the chance for successful 154 innovation.

A current real-life example is the COVID-19 pandemic, an occurrence that was not foreseen because of which only relatively small and scattered efforts of research have been conducted prior to the pandemic. The current R&I race to develop a cure and vaccine against COVID-19 would have greatly benefitted from an advanced knowledge on coronaviruses, obtained through biotechnology discovery research

[10, 11]. Of course, in hindsight it is easy to highlight what should have been done. In 160 161 practice, there are several million viruses in the world, over 200 of which are known to infect humans. Conducting extensive research on all these viruses in parallel 162 163 would be too labor-intensive and unsustainable from an economical point of view. However, the current crisis reveals the advantage in time the use of scenario 164 indicators can offer to international and local organizations dealing with public health. 165 Such indicators might have flagged previous smaller outbreaks of other 166 coronaviruses such as SARS (severe acute respiratory syndrome) and MERS 167 168 (Middle East respiratory syndrome) in the last two decades. These outbreaks could 169 then have been predictive for scenarios in which coronaviruses would become a 170 major threat to human health, and could have triggered dedicated funding to advance 171 specific biotechnological knowhow, as well as to develop strategies to minimize the 172 spread of this type of disease. Major funding is currently being gathered to mitigate the consequences of the COVID-19 crisis, including \$8 billion pledged by world 173 174 leaders to support dedicated R&I [12]. However, today's continuing need to conduct 175 significant biotechnology discovery research means that time, not necessarily funding 176 per se, is a bottleneck. Along the same lines, developing scenarios today to understand how the future may unfold in the context of the COVID-19 pandemic, 177 could help anticipate the long-term consequences of the actions that are being taken 178 179 and could allow countries, states and communities to react to the crisis more effectively. In the context of the scenarios presented in Figure 3, the current 180 pandemic emerges as a relevant indicator for the Food emergency scenario. A 181 global economic crisis may put critical agricultural supply chains at risk, such that 182 183 food security becomes an even greater issue in certain world regions.

184

185 Concluding Remarks

The above biotechnology examples demonstrate the risk of a low innovation output when the founding knowhow obtained from discovery research is not readily available and accessible in a useable format. The timely availability of founding knowhow may greatly improve by adopting the use of learning scenarios and the tracking of progress against indicators for these scenarios. To make such an approach effective, several outstanding issues need to be addressed first (Outstanding Questions)

We strongly believe that to improve the innovation output, the discussion should go 194 beyond "financial instruments" and "creativity". Rather, we would recommend to look 195 at how the innovation ecosystem functions [13]: To maximize the utilization of 196 197 advances in knowhow, the current working principles between academia, value chain players and society would benefit from extensive review. Biological science needs a 198 199 continuous cross-stakeholder interaction to move more efficiently from discovery to innovation. To steer biotechnological R&I more efficiently, an open innovation 200 201 governance concept to deal with pre-competitive and competitive big data information and activities is an absolute pre-requisite 202

203 We therefore propose to install virtual innovation workflows spanning academia and 204 value chain players to address societal demands (Fig. 4). The idea is to set up dedicated ecosystem knowledge bases that serve, for example, the medical, 205 agricultural or industrial biotechnology sectors or serve a broad innovation field such 206 as the microbiome. These ecosystem knowledge bases should harbor harmonized 207 208 and curated data in formats tailored to stakeholder use requirements. Such requirements can be defined for each of the biotechnology fields in a two-step 209 process. First the generic workflow at handover points between academia and value 210 211 chain players should be described, followed by the data and format requirements in 212 this generic workflow, which would be necessary to start. These processes should ideally be described in both directions. In addition, users extracting information with 213 214 their own software, if private, should commit to upload outcomes that are made anonymous, so that the next round of experimental questions can consider advanced 215 216 information, and the knowledge base increases over time both in scope and in predictiveness. 217

218

To make this workable and sustainable, appropriate business models and governance concepts to deal with, among others, data ownership and intellectual property need to be developed, and dedicated data stewardship teams need to be installed. Setting this up will likely need several rounds of optimization to reach the best compromise between stakeholder interests. Yet, it is well positioned to improve

193

the overall flow of innovation to the market and to offer the desired flexibility to dealwith upcoming trends in an ever-changing world.

226 Acknowledgments

- 227 The authors thank Dr. Axel Sommer for his support and guidance on Scenario
- 228 Analysis carried out under CropBooster-P. This project is funded by European Union
- Horizon 2020 Research and innovation Programme under grant agreement 817690.

230 *Disclaimer Statement

- Responsibility for the information and views set out in this article lies entirely with the
- authors and do not necessarily reflect the official opinion of the European
- 233 Commission.

Figure 1. Innovation flow. In the coming 15 years, the market will be served by R&D that is performed today. Different biotechnology sectors address changes in demand by repositioning and emphasizing what is in today's pipeline. New R&D and public research ideally address the demand of the future market. Scenario analysis is well suited to narrow down the most promising fields of investigation and to address the unmet needs of future markets. R: research; D: development.

Figure 2. Trends and uncertainties. Trends are considered developments going in
a certain direction, while uncertainties can determine distinct outcomes with very
different implications. Here the two most extreme ways that the uncertainties could
play out are presented. Examples of specific uncertainties clustered around three
more general themes are provided in the footnote.

The exercise delivered four contrasting learning scenarios by detailing out specific
aspects of possible future worlds and making them as concrete and vivid as possible.

- 247 (Fig. 3). As the selected trends and uncertainties deal with society, environment,
- innovation and policy, the learning scenarios helped to characterize implications not
- only for the future of agriculture in Europe, which was the initial scope of the scenario
- building, but they can also serve to aid decisions on future research and innovation
- 251 (*R&I*) investments in other fields of biotechnology globally.

Figure 3. Learning scenarios. Four contrasting learning scenarios enable us to
 delineate the option space for the direction and context of future biotechnology. Bio innovation: Biotechnology solutions are intensively used and sustainably provide

sufficient high-quality food and large volume feedstock for a thriving bioeconomy; My 255 256 choice: Health and sustainability concerns drive all sectors to be diverse and 257 transparent, meeting the needs and preferences of individuals, personalized medicine and nutrition are the norm; REJECTech: Consumers have little trust in 258 politicians, scientists and big industry. Society is highly polarized and rejects 259 biotechnology-derived products and services, despite dissatisfaction about missed 260 opportunities, such as a broad adoption of the bioeconomy due to limited agricultural 261 production; **Food emergency**: Due to severe environmental degradation, the world is 262 263 struggling to fulfill basic food demand. In response to the crisis, global adoption of innovation, including biotechnology, occurs to mitigate impacts. 264

265 Figure 4. Outline of a future "virtual innovation workflow" driven by

biotechnology big data governance. An example is given for agricultural innovation 266 267 in Europe. To meaningfully contribute to the EU Green Deal, a rejuvenation of the agricultural ecosystem including academia, breeding and R&D companies, farm 268 269 supply industry and farmers, is desirable. Required innovations should address 270 environmental sustainability, impacts of increased weather volatility, climate change 271 and associated pest and disease development, the European protein plan, development of more healthy and nutritious food, and an enablement of the bio-272 economy. It should offer a lever to improve farm economics structurally through 273 274 product branding and traceability. The novelty of the proposed "virtual innovation workflow" is the bidirectional handover of outcomes and the holistic integration of 275 276 data coming from plant, microbial, soil, agronomy, robotization, machine learning, modelling and weather/climate disciplines. Critical success factors are, amongst 277 278 others, the alignment of key performance indicators of stakeholders, incentives to participate, an open innovation attitude, a common benchmark to measure progress, 279 280 smartly located research field stations, dedicated data centers with a user-oriented data curation, harmonization, storage and display approach, and an agreeable data 281 282 governance concept. A pipeline of consecutive innovations can be primed by raising, 283 over time, the requirements to pass successfully the formal variety testing and 284 registration process. Customer demand (not shown) is in this example translated to requirements for official variety testing trials that e.g. meet progressively increasing 285 286 levels of sustainability.

287

288 **References**


- Schoemaker P. (1995) "Scenario planning: a tool for strategic thinking" from
 Sloan Management Review 36 (2) 25-40, Cambridge, Mass.: Massachussetts
 Institute of Technology
- 292 2. International Business (2012) Chapter 8.5 Scenario Planning and Analysis.
- Saylor Academy, 442-448: <u>https://saylordotorg.github.io/text_international-</u>
 <u>business/s12-05-scenario-planning-and-analysis.html</u>
- Gillespie I., Wells R., Bartsev A., Philp J. (2011) Industrial Biotechnology,
 Volume: 7 Issue 4: 267-268: https://doi.org/10.1089/ind.2011.7.267
- 4. European Commission. (2018) A Sustainable Bioeconomy for Europe:
- Strengthening the Connection Between Economy, Society and the Environment.Updated Bioeconomy Strategy.
- Steinwand, M.A., Ronald, P.C. (2020) Crop biotechnology and the future of food.
 Nat Food 1, 273–283.
- McLaren D., Markusson N. (2020) The co-evolution of technological promises,
 modelling, policies and climate change targets. *Nat. Clim. Chang.* 10, 392–397.
- Małyska A, Markakis M.N., Pereira C.F., Cornelissen M. (2019) The Microbiome:
 A Life Science Opportunity for Our Society and Our Planet. Trends Biotechnol.;
 37(12):1269-1272.
- 307 8. Genomics England (<u>https://www.genomicsengland.co.uk/</u>) The 100,000
 308 Genomes Project.
- 309 9. European Commission. (2018) Report from the Commission to the Council and
- the European Parliament on the development of plant proteins in the European
 Union, COM/2018/757 final
- 10. The race against COVID-19 (2020). Nat. Nanotechnol. 15, 239–240
- 313 11. Graham B. S. Rapid COVID-19 vaccine development Science. 2020;368
 314 (6494):945-946.
- 12. Reuters (2020) World leaders pledge \$8 billion to fight COVID-19 but U.S. steers
- 316 clear (https://www.reuters.com/article/us-health-coronavirus-eu-virus/world-
- 317 leaders-pledge-8-billion-to-fight-covid-19-but-us-steers-clear-idUSKBN22G0RM)
- 13. Anadon L. D., Chan G., Harley A. G., et al. (2016) Making technological
- innovation work for sustainable development. Proc Natl Acad Sci USA, 113(35),
- 320 9682-9690

Outstanding Questions

- 1. How to motivate all relevant stakeholders to develop jointly a common understanding of learning scenarios and their impact?
- 2. How to ensure that scenarios are timely updated to address specific developments over time, including aspects that were not covered during earlier scenario exercises?
- 3. How to organise the tracking of indicators and the dissemination of weaker and stronger signals that may indicate direction of change before any of the scenarios fully materializes?
- 4. How to improve the quality of scenario development and its utilization by the latest developments in digitalization and AI?

Original Figure File

Click here to access/download Original Figure File TIBS2020 figures_orignal.pptx Figure Figure 1



Trends

1) Aging Population	16) Do-it-Yourself	31) Plant Beneficial Microbes
2) AI & Big Data	17) E-Commerce	32) Population Growth
3) Altered Genetic Resources Circulation	18) Economic Pressure on Farms	33) Power of the Online Public
4) Alternative Nutrition Sources	19) Electrification	34) Product & Research Regulation
5) Animal Welfare	20) Environmental Concerns	35) Public Engagement in Research
6) Biofortification	21) Fair Trade	36) Renewable Energy
7) Biotech	22) Globalization	37) Resource Scarcity
8) Block chain	23) Healthy Lifestyle	38) Rising Disposable Income
9) Cheaper Food	24) ICT on the Rise	39) Risk Sensitivity
10) Circular Bioeconomy	25) Increased Mechanization	40) Robotics
11) Climate Change	26) Intellectual Property	41) Self-Tracking / Quantified Self
12) Cultivar / Species Mixtures	27) Land-Use Pressure	42) Sustainability
13) Decline of Pollinators & Biodiversity	28) NBTs & Genetic Modification	43) Transparency
14) Declining Chemistry for Pest Control	29) Offering of Meat Alternatives	44) Urban Farming / Greenhouses
15) Diet-related Chronic Diseases	30) Organic Farming	45) Urbanization


Uncertainties

imited impact Healthy, small population	Impact of environmental changes ¹	Heavy negative impact
Healthy, small population		
<i>r</i> 11	Development of demography ²	Large, unhealthy population
Stable, prosperous economy	Development of the economy ³	Poor, volatile economy
Collaborative, open markets	Development of the political environment	Isolationism
Not important	Importance of sustainability ⁴	Important & relevant
Focus on food	Role of the bioeconomy: food vs. non-food	Strong demand for nonfood
Breakthroughs & adoption	Development of advanced biotech	Ban of wide range of biotech
Breakthroughs & adoption	Development of non-biological tech ⁵	Failures and abandonment
/ery high	Influence and reputation of scientists	Very low
	ollaborative, open markets lot important ocus on food reakthroughs & adoption reakthroughs & adoption	ollaborative, open marketsDevelopment of the political environmentlot importantImportance of sustainability4ocus on foodRole of the bioeconomy: food vs. non-foodreakthroughs & adoptionDevelopment of advanced biotechreakthroughs & adoptionDevelopment of non-biological tech5

1 e.g., climate change, resources scarcity, development of pests, loss in biodiversity,...

2 e.g., size of population, age, chronic diseases,... 3 e.g., prices, income, equality,... 4 e.g., environmental concerns, animal welfare, organic farming,... 5 e.g., robots, AI, VR/AR, blockchain,...

Figure 2



Different questions depending on crop and location Harmonisation and breeders curation of vast collection of published work Progressive sustainability standards in variety testing will offer breeders **Different questions** scientists focus and global competitiveness depending on biology and discipline